Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Program for Ripretinib in Patients With Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment With Prior Therapies

Next Previous
Search
Trial Profile

Expanded Access Program for Ripretinib in Patients With Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment With Prior Therapies

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ripretinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Expanded access; Therapeutic Use
  • Sponsors Deciphera Pharmaceuticals

Most Recent Events

  • 27 May 2020 Status changed from recruiting to completed.
  • 19 Feb 2020 According to a Deciphera Pharmaceuticals media release, the company intends to use the net proceeds from the share offering to fund this trial
  • 19 Feb 2020 According to a Deciphera Pharmaceuticals media release, the company intends to use the net proceeds from the share offering to fund this trial.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top